Tag: biotechnology
-
Environmental Biomarker Start-Up Gains $16M in Early Funds
A new company developing diagnostics for neurological and other disorders based on environmental exposures is raising $16 million in venture funds.
-
CEPI Assessing Advanced RNA Nanoparticle Vaccine
An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics.
-
Nanotech Enzyme Process Boosts T-Cell Cancer Therapies
A bioengineering team devised techniques for feasibly adding cancer-killing enzymes to engineered immune cells that in lab mice kill solid-tumor and blood cancer cells.
-
BioNTech to Provide Personal Cancer Immunotherapies in UK
The biotechnology company BioNTech SE is partnering with the U.K. government to provide up to 10,000 personalized cancer immunotherapy treatments by 2030.
-
Biotech Alliance Creating Circular RNA Cancer Drug
A partnership of biotechnology components and therapy companies aims to develop new drugs made from circular forms of RNA, starting with a colorectal cancer treatment.
-
Protein Chemistry Biotech Gains Collaboration, Venture Funds
An enterprise discovering new drugs with optical light-based protein chemistry is emerging from stealth, including work with biopharmaceutical company Genentech.
-
Infographic – Biotech Index Struggles to Regain Ground
NBI is showing signs of life, rising somewhat from its low point for the year and since the end of the third quarter, but still down almost 12 percent since the start of the year.
-
Company Started for Gene Editing Rare Inherited Diseases
A new enterprise is formed to develop gene-editing therapies for mitochondrial disorders, rare inherited mutations in the energy centers of cells.
-
Peptide Discovery Company to Gain $3.3B in Licensing Deals
A discoverer of therapeutic peptides signed licensing deals in the past few days with two drug makers that could bring the company as much as $3.3 billion.
-
Food Protein Biotech Adds €4M in Seed Funds
A new company creating protein ingredients for food products from carbon dioxide converted by engineered bacteria is raising €4 million more in seed funds.